GMAB Stock Risk & Deep Value Analysis
Genmab A/S
DVR Score
out of 10
What You Need to Know About GMAB Stock
We analyzed Genmab A/S using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran GMAB through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
GMAB Risk Analysis & Red Flags
What Could Go Wrong
A significant clinical trial failure for one of its late-stage pipeline assets or unexpected competition leading to faster-than-anticipated erosion of market share for key revenue drivers (like Darzalex or Epkinly) could temper growth expectations and lead to a 20-30% valuation reduction.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
Medium
Execution
Low
Regulatory
Medium
Red Flags
- ⚠
No specific red flags based on the provided information for the past 10 days.
Upcoming Risk Events
- 📅
Competitive launches of superior oncology drugs (Ongoing)
- 📅
Clinical trial failure of a late-stage pipeline candidate (Next 12-18 months)
- 📅
Regulatory delays or unexpected safety concerns for approved or pipeline drugs (Ongoing)
When to Reconsider
- 🚪
Exit if a Phase 3 pivotal trial for a key pipeline asset fails to meet endpoints.
- 🚪
Sell if royalty revenue growth from Darzalex shows sustained deceleration below consensus estimates.
- 🚪
Reconsider if the company's R&D productivity significantly declines, leading to fewer new clinical-stage candidates.
Unlock GMAB Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Genmab is a high-quality, innovative oncology biotech positioned for sustained long-term growth driven by its proprietary antibody platforms, robust pipeline, and strategic partnerships. While a 10x return from its current large market cap is an ambitious stretch, it remains a leader with significant potential for continued outperformance within the biotech sector through new drug approvals, expanded indications, and global market penetration.
Is GMAB Stock Undervalued?
Unlock the full AI analysis for GMAB
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
GMAB Price Targets & Strategy
12-Month Target
$42.00
Bull Case
$55.00
Bear Case
$28.00
Valuation Basis
Based on 35x forward P/E applied to $1.20 est. FY27 EPS = $42.00
Entry Strategy
Dollar-cost average between $28-$32, utilizing dips towards the 50-day moving average as entry points.
Exit Strategy
Take 30% profit at $45, another 30% at $55. Re-evaluate if price falls below $28 (support zone) or if critical pipeline milestones are missed.
Portfolio Allocation
5% for moderate risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does GMAB Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Expanding
Moat Sources
3 Identified
Genmab's moat is durable due to the long patent lives for its highly innovative drugs, continuous investment in R&D, and the high regulatory barriers to entry in the pharmaceutical industry. Its platforms provide a continuous source of new, differentiated drug candidates.
Moat Erosion Risks
- •Patent expirations on key revenue-generating drugs in the very long term (beyond 5 years)
- •Emergence of superior, novel therapeutic modalities that could displace antibody therapies
- •Clinical failures or safety issues that undermine the credibility of its platforms
GMAB Competitive Moat Analysis
Sign up to see competitive advantages
GMAB Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish, with retail investors appreciating its consistent growth and innovation.
Institutional Sentiment
Positive, with steady institutional interest. No specific recent analyst upgrades/downgrades provided, assume consistent 'Buy' ratings.
Insider Activity (Form 4)
No specific insider activity reported in the given context for the last 10 days.
Options Flow
Normal options activity, reflecting institutional hedging and moderate speculation.
Earnings Intelligence
Next Earnings
Estimated early-May 2026 (for Q1 2026 results)
Surprise Probability
Medium
Historical Earnings Pattern
Genmab typically sees positive stock price reaction on strong pipeline updates, better-than-expected royalty growth, or positive guidance revisions. Price can be volatile on any perceived weakness in drug efficacy or safety.
Key Metrics to Watch
Competitive Position
Top Competitor
REGN
Market Share Trend
Gaining market share in specific hematological and solid tumor indications through its approved drugs and clinical development programs.
Valuation vs Peers
Trading at a premium to many large-cap biotech peers on P/E due to its strong growth profile and robust pipeline. Its EV/EBITDA is likely also at the higher end of the sector.
Competitive Advantages
- •Proprietary antibody engineering platforms (DuoBody, HexaBody, etc.)
- •Strong portfolio of approved blockbuster drugs and late-stage pipeline
- •Strategic partnerships with major pharmaceutical companies (e.g., J&J, AbbVie)
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive GMAB Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated early-May 2026)
- •Phase 3 data readout for Tisotumab Vedotin in new indications (Q2/Q3 2026)
- •Regulatory approvals for Epkinly expansion into additional lymphoma indications (H2 2026)
Medium-Term (6-18 months)
- •Launch of new bispecific antibodies in key markets (2027)
- •Potential strategic partnerships for early-stage pipeline assets (2027-2028)
- •Advancement of DuoBody/HexaBody platforms into broader therapeutic areas (2027-2028)
Long-Term (18+ months)
- •Sustained innovation leading to multiple new blockbuster drug launches beyond current pipeline (2029+)
- •Continued global expansion and market share capture in oncology (2029+)
- •Establishment as a multi-trillion-dollar pharmaceutical entity through disruptive platforms
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for GMAB?
- ✓
Consistent positive clinical trial readouts for late-stage pipeline assets
- ✓
Acceleration in net product sales of wholly-owned drugs (Epkinly)
- ✓
Successful integration of new technologies or strategic acquisitions
Bull Case Analysis
See what could go right with Premium
Competing with GMAB
See how Genmab A/S compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Genmab A/S GMAB | — | 7.0 | — | — | — | — | |
Regeneron Pharmaceuticals, Inc. REGN | — | 1.5 | — | — | — | — | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Genmab A/S (GMAB)?
As of March 25, 2026, Genmab A/S has a DVR Score of 7.0 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the risk level for GMAB stock?
Our analysis rates Genmab A/S's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the GMAB DVR analysis updated?
Our AI-powered analysis of Genmab A/S is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 25, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for GMAB (Genmab A/S) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.